Ocular Therapeutix (OCUL) EBITDA Margin Growth (3y) (2017 - 2026)

Ocular Therapeutix (OCUL) EBITDA Margin Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -1,211.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 7,794.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Ocular Therapeutix 1.91 Bn 1.91 Bn 9.46 Mn -69,686.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -69,686.00
Dec 31, 2025 -38,893.00
Sep 30, 2025 -29,229.00
Jun 30, 2025 -34,020.00
Mar 31, 2025 -46,224.00
Dec 31, 2024 -14,943.00
Sep 30, 2024 -13,751.00
Jun 30, 2024 -9,248.00
Mar 31, 2024 6,151.00
Dec 31, 2023 5,971.00
Sep 30, 2023 11,095.00
Jun 30, 2023 100,438.00
Mar 31, 2023 46,819.00
Dec 31, 2022 81,107.00
Sep 30, 2022 261,174.00
Jun 30, 2022 316,056.00
Mar 31, 2022 386,030.00
Dec 31, 2021 328,252.00
Sep 30, 2021 281,441.00
Jun 30, 2021 192,056.00